| Bioactivity | Grisnilimab (WT1), a IgG2a monoclonal antibody anti-CD7, is a tumor suppressor involved in the etiology of Wilms' tumor. Grisnilimab regulates the transcription of multiple target genes and may participate in the post-transcriptional processing of RNA[1]. |
| Name | Grisnilimab |
| CAS | 2367001-70-3 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Scharnhorst V, et al. WT1 proteins: functions in growth and differentiation. Gene. 2001 Aug 8;273(2):141-61. [2]. Hertler AA, et al. An immunotoxin for the treatment of T-acute lymphoblastic leukemic meningitis: studies in rhesus monkeys. Cancer Immunol Immunother. 1989;28(1):59-66. |